glyburide has been researched along with Obesity in 88 studies
Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide
glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin has been reported to reduce the risk of pre-eclampsia." | 8.98 | Metformin for prevention of hypertensive disorders of pregnancy in women with gestational diabetes or obesity: systematic review and meta-analysis of randomized trials. ( Abdi, A; Kalafat, E; Khalil, A; Sukur, YE; Thilaganathan, B, 2018) |
| "To examine the effect of obesity on maternal and neonatal outcomes in women diagnosed with gestational diabetes mellitus (GDM) and managed with diet only, glyburide, or insulin." | 7.78 | The effect of maternal obesity on pregnancy outcomes of women with gestational diabetes controlled with diet only, glyburide, or insulin. ( Desch, C; Istwan, N; Joy, S; Rhea, D; Roman, A; Saltzman, D; Stanziano, G, 2012) |
| "Use of glyburide and obesity may both be risk factors for acute pancreatitis." | 7.71 | Obesity and treatment of diabetes with glyburide may both be risk factors for acute pancreatitis. ( Blomgren, KB; Steineck, G; Sundström, A; Wiholm, BE, 2002) |
| "In this population of obese Hispanic patients with type 2 diabetes, sibutramine combined with glibenclamide therapy achieved weight loss for up to 12 months and was associated with better glycemic control than placebo." | 5.11 | Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial. ( Berber, A; Campos-Franco, E; Fanghänel, G; Martínez-Rivas, L; Sánchez-Reyes, L; Yamamoto, J, 2004) |
| " At presentation, the acute C-peptide response to glucagon in obese DKA patients was lower than in patients with hyperglycemia (P < 0." | 5.08 | Sulfonylurea treatment prevents recurrence of hyperglycemia in obese African-American patients with a history of hyperglycemic crises. ( Clark, WS; Steen, MT; Umpierrez, GE, 1997) |
| "Metformin has been reported to reduce the risk of pre-eclampsia." | 4.98 | Metformin for prevention of hypertensive disorders of pregnancy in women with gestational diabetes or obesity: systematic review and meta-analysis of randomized trials. ( Abdi, A; Kalafat, E; Khalil, A; Sukur, YE; Thilaganathan, B, 2018) |
| " On the other hand, treatment of obese patients with metformin significantly reduced the incidence of myocardial infarction and of mortality diabetes related." | 4.80 | [Should the occurrence of a first coronary event change the management of diabetes?]. ( Dubois-Laforgue, D; Timsit, J, 2000) |
| " Arcade arteriolar diameters were measured following muscle contraction or application of the KATP opener cromakalim before and after glibenclamide application." | 3.79 | Impaired vascular KATP function attenuates exercise capacity in obese zucker rats. ( Clemmer, JS; Gowdey, AR; Hester, RL; Lu, S; Mittwede, PN; Xiang, L, 2013) |
| "To examine the effect of obesity on maternal and neonatal outcomes in women diagnosed with gestational diabetes mellitus (GDM) and managed with diet only, glyburide, or insulin." | 3.78 | The effect of maternal obesity on pregnancy outcomes of women with gestational diabetes controlled with diet only, glyburide, or insulin. ( Desch, C; Istwan, N; Joy, S; Rhea, D; Roman, A; Saltzman, D; Stanziano, G, 2012) |
| "Use of glyburide and obesity may both be risk factors for acute pancreatitis." | 3.71 | Obesity and treatment of diabetes with glyburide may both be risk factors for acute pancreatitis. ( Blomgren, KB; Steineck, G; Sundström, A; Wiholm, BE, 2002) |
| "We have studied the pharmacokinetics and pharmacodynamics of glyburide during long-term therapy in 20 patients with type II diabetes mellitus." | 3.68 | The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics. ( Antal, EJ; Jaber, LA; Slaughter, RL; Welshman, IR, 1993) |
| "Glyburide and other sulfonylureas consistently enhance receptor binding in cells from patients with non-insulin-dependent diabetes mellitus, whereas no effects and mixed effects have been demonstrated in cells from patients with insulin-dependent diabetes mellitus and in normal cells, respectively." | 3.67 | Dual actions of sulfonylureas and glyburide. Receptor and post-receptor effects. ( Gavin, JR, 1985) |
| "Troglitazone treatment increased serum adiponectin levels nearly threefold." | 2.71 | Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. ( Aroda, V; Bandukwala, R; Baxi, S; Carter, L; Ciaraldi, TP; Henry, RR; Kong, AP; Mudaliar, SR; Phillips, SA, 2003) |
| "Glyburide treatment of diabetes decreased CRP and did so even though body weight increased." | 2.71 | Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy. ( Bar, RS; Goldner, WS; Haynes, WG; Putz, DM; Sivitz, WI, 2004) |
| "In patients with type 2 diabetes, intensive blood-glucose control with insulin or sulphonylurea therapy decreases progression of microvascular disease and may also reduce the risk of heart attacks." | 2.69 | Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. ( , 1998) |
| " Premixed 70% NPH/30% Regular insulin was taken before supper, and the dosage was adjusted weekly by an algorithm seeking nearly normal fasting glycemia." | 2.67 | Combined therapy for obese type 2 diabetes: suppertime mixed insulin with daytime sulfonylurea. ( Bingham, P; Garrison, C; Hart, J; McDaniel, P; Riddle, M, 1992) |
| "Obesity is often associated with hyperinsulinemia due to insulin resistance." | 1.72 | E4orf1-induced reduction in endogenous insulin level is independent of pancreas endocrine function. ( Akheruzzaman, M; Dhurandhar, NV; Feizy, Z; Hegde, V; Shin, AC; Siddik, MAB, 2022) |
| "Maternal obesity and gestational diabetes mellitus (GDM) are two increasingly common and important obstetric complications that are associated with severe long-term health risks to mothers and babies." | 1.42 | Endoplasmic reticulum stress is increased in adipose tissue of women with gestational diabetes. ( Lappas, M; Liong, S, 2015) |
| "Obesity is associated with impaired functional hyperemic response." | 1.35 | Adipocyte-derived factor reduces vasodilatory capability in ob-/ob- mice. ( Hester, RL; Xiang, L, 2009) |
| "Insulin resistance is a key feature of type 2 diabetes mellitus." | 1.32 | Urinary PC-1 and N-acetyl-beta-D-glucosaminidase activity in patients with type 2 diabetes treated with metformin, gliclazide or glibenclamide. ( Antić, S; Bogicević, M; Milojković, M; Mitić-Zlatković, M; Stefanović, V; Stojiljković, S; Vlahović, P, 2003) |
| "Some patients with type 2 diabetes present with ketoacidosis and require insulin treatment." | 1.30 | Atypical ketoacidosis in type 2 diabetes. ( Goldberg, RB; Machado, R, 1998) |
| " In conclusion, isolated mesenteric arteries from obese Zucker rats do not show relevant structural changes, and the pharmacodynamic behaviour of such vessels appears to be the same as that of control preparations." | 1.29 | Pharmacodynamic behaviour of isolated resistance vessels obtained from hypertensive-diabetic rats. ( Kam, KL; Pfaffendorf, M; van Zwieten, PA, 1996) |
| "A total of 40 NIDDM patients were examined (24 females and 16 males) with a mean age of 55." | 1.29 | [Comparison of two treatment models in type-II diabetic patients with poor metabolic control: Preformed combination of glibenclamide 2,5 mg + metformin 400 mg or mono-therapy with sulfonylurea at maximal doses? An evaluation at six months]. ( Cavallo, P; D'Argenzio, R; Merante, D; Morelli, A, 1996) |
| " 68% of all SH-cases did with a dosage of 1-3 mg glibenclamide a day, 28% with 1 mg a day." | 1.28 | [Treatment of newly diagnosed type II diabetic patients with special reference to prescribing glibenclamide in low doses]. ( Bothe, E; Dempe, A; Hanisch, R; Häntzschel, U; Wurlitzer, M, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 39 (44.32) | 18.7374 |
| 1990's | 19 (21.59) | 18.2507 |
| 2000's | 14 (15.91) | 29.6817 |
| 2010's | 13 (14.77) | 24.3611 |
| 2020's | 3 (3.41) | 2.80 |
| Authors | Studies |
|---|---|
| Akheruzzaman, M | 1 |
| Hegde, V | 1 |
| Siddik, MAB | 1 |
| Feizy, Z | 1 |
| Shin, AC | 1 |
| Dhurandhar, NV | 1 |
| Kuo, YY | 2 |
| Tsai, HY | 1 |
| Kuo, YM | 2 |
| Tzeng, SF | 1 |
| Chen, PS | 2 |
| Hsu, PH | 1 |
| Lin, YT | 2 |
| Chen, PC | 2 |
| Lin, JK | 1 |
| Chen, JC | 1 |
| Wu, SN | 1 |
| da Silva Franco, CC | 1 |
| Previate, C | 2 |
| de Barros Machado, KG | 1 |
| Piovan, S | 1 |
| Miranda, RA | 2 |
| Prates, KV | 2 |
| Moreira, VM | 2 |
| de Oliveira, JC | 2 |
| Barella, LF | 2 |
| Gomes, RM | 2 |
| Francisco, FA | 2 |
| Martins, IP | 2 |
| Pavanello, A | 2 |
| Ribeiro, TA | 2 |
| Tófolo, LP | 2 |
| Malta, A | 2 |
| de Souza, AA | 1 |
| Alves, VS | 2 |
| da Silva Silveira, S | 1 |
| Marçal Natali, MR | 1 |
| Fernando Besson, JC | 1 |
| de Morais, H | 1 |
| de Souza, HM | 1 |
| de Sant Anna, JR | 2 |
| Alves de Castro Prado, MA | 1 |
| de Freitas Mathias, PC | 1 |
| Lin, YW | 1 |
| Liu, PS | 1 |
| Pook, KA | 1 |
| Wei, LN | 1 |
| Kalafat, E | 1 |
| Sukur, YE | 1 |
| Abdi, A | 1 |
| Thilaganathan, B | 1 |
| Khalil, A | 1 |
| Derosa, G | 1 |
| Cicero, AF | 1 |
| Franzetti, IG | 1 |
| Querci, F | 1 |
| Carbone, A | 1 |
| Piccinni, MN | 1 |
| D'Angelo, A | 1 |
| Fogari, E | 1 |
| Maffioli, P | 1 |
| Lu, S | 2 |
| Xiang, L | 4 |
| Clemmer, JS | 1 |
| Gowdey, AR | 1 |
| Mittwede, PN | 1 |
| Hester, RL | 3 |
| Iwasaki, Y | 1 |
| Shimomura, K | 1 |
| Kohno, D | 1 |
| Dezaki, K | 1 |
| Ayush, EA | 1 |
| Nakabayashi, H | 1 |
| Kubota, N | 1 |
| Kadowaki, T | 1 |
| Kakei, M | 1 |
| Nakata, M | 1 |
| Yada, T | 1 |
| Henriksbo, BD | 1 |
| Lau, TC | 1 |
| Cavallari, JF | 1 |
| Denou, E | 1 |
| Chi, W | 1 |
| Lally, JS | 1 |
| Crane, JD | 1 |
| Duggan, BM | 1 |
| Foley, KP | 1 |
| Fullerton, MD | 1 |
| Tarnopolsky, MA | 1 |
| Steinberg, GR | 1 |
| Schertzer, JD | 1 |
| Honda, H | 1 |
| Nagai, Y | 1 |
| Matsunaga, T | 1 |
| Okamoto, N | 1 |
| Watanabe, Y | 1 |
| Tsuneyama, K | 1 |
| Hayashi, H | 1 |
| Fujii, I | 1 |
| Ikutani, M | 1 |
| Hirai, Y | 1 |
| Muraguchi, A | 1 |
| Takatsu, K | 1 |
| Roche, C | 1 |
| Besnier, M | 1 |
| Cassel, R | 1 |
| Harouki, N | 1 |
| Coquerel, D | 1 |
| Guerrot, D | 1 |
| Nicol, L | 1 |
| Loizon, E | 1 |
| Remy-Jouet, I | 1 |
| Morisseau, C | 1 |
| Mulder, P | 1 |
| Ouvrard-Pascaud, A | 1 |
| Madec, AM | 1 |
| Richard, V | 1 |
| Bellien, J | 1 |
| Liong, S | 1 |
| Lappas, M | 1 |
| Franco, CCS | 1 |
| Moraes, AMP | 1 |
| Matiusso, CCI | 1 |
| Rigo, KP | 1 |
| Almeida, DL | 1 |
| Prado, MAAC | 1 |
| Mathias, PCF | 1 |
| Fan, LH | 1 |
| Tian, HY | 1 |
| Wang, J | 1 |
| Huo, JH | 1 |
| Hu, Z | 1 |
| Ma, AQ | 1 |
| Cao, YX | 1 |
| Hodnett, BL | 1 |
| Dearman, JA | 1 |
| Carter, CB | 1 |
| Mazaki-Tovi, S | 1 |
| Romero, R | 1 |
| Vaisbuch, E | 1 |
| Erez, O | 1 |
| Mittal, P | 1 |
| Chaiworapongsa, T | 1 |
| Kim, SK | 1 |
| Pacora, P | 1 |
| Yeo, L | 1 |
| Gotsch, F | 1 |
| Dong, Z | 1 |
| Yoon, BH | 1 |
| Hassan, SS | 1 |
| Kusanovic, JP | 1 |
| Fuller, W | 1 |
| Aneja, A | 1 |
| Russell, GV | 1 |
| Jones, LB | 1 |
| Hester, R | 1 |
| Joy, S | 1 |
| Roman, A | 1 |
| Istwan, N | 1 |
| Rhea, D | 1 |
| Desch, C | 1 |
| Stanziano, G | 1 |
| Saltzman, D | 1 |
| Phillips, SA | 1 |
| Ciaraldi, TP | 1 |
| Kong, AP | 1 |
| Bandukwala, R | 1 |
| Aroda, V | 1 |
| Carter, L | 1 |
| Baxi, S | 1 |
| Mudaliar, SR | 1 |
| Henry, RR | 2 |
| Stefanović, V | 1 |
| Antić, S | 1 |
| Mitić-Zlatković, M | 1 |
| Stojiljković, S | 1 |
| Milojković, M | 1 |
| Bogicević, M | 1 |
| Vlahović, P | 1 |
| Mori, Y | 1 |
| Komiya, H | 1 |
| Kurokawa, N | 1 |
| Tajima, N | 1 |
| Kellerer, M | 1 |
| Jakob, S | 1 |
| Linn, T | 1 |
| Haslbeck, M | 1 |
| Aminorroaya, A | 1 |
| Janghorbani, M | 1 |
| Ramezani, M | 1 |
| Haghighi, S | 1 |
| Amini, M | 1 |
| Sánchez-Reyes, L | 1 |
| Fanghänel, G | 1 |
| Yamamoto, J | 1 |
| Martínez-Rivas, L | 1 |
| Campos-Franco, E | 1 |
| Berber, A | 1 |
| Putz, DM | 1 |
| Goldner, WS | 1 |
| Bar, RS | 1 |
| Haynes, WG | 1 |
| Sivitz, WI | 1 |
| Inukai, K | 1 |
| Watanabe, M | 1 |
| Nakashima, Y | 1 |
| Sawa, T | 1 |
| Takata, N | 1 |
| Tanaka, M | 1 |
| Kashiwabara, H | 1 |
| Yokota, K | 1 |
| Suzuki, M | 1 |
| Kurihara, S | 1 |
| Awata, T | 1 |
| Katayama, S | 1 |
| DeFronzo, RA | 1 |
| Goodman, AM | 1 |
| Jaber, LA | 1 |
| Antal, EJ | 1 |
| Slaughter, RL | 1 |
| Welshman, IR | 1 |
| Pelikánová, T | 1 |
| Kohout, M | 1 |
| Válek, J | 1 |
| Kazdová, L | 1 |
| Base, J | 1 |
| Suh, KI | 1 |
| Murata, C | 1 |
| Song, YM | 1 |
| Joyce, M | 1 |
| Gumbiner, B | 1 |
| Ditzler, TM | 1 |
| Miller, JL | 1 |
| Salman, K | 1 |
| Shulman, LH | 1 |
| Rose, LI | 1 |
| Tokuyama, Y | 1 |
| Fan, Z | 1 |
| Furuta, H | 1 |
| Makielski, JC | 1 |
| Polonsky, KS | 1 |
| Bell, GI | 1 |
| Yano, H | 1 |
| Kam, KL | 1 |
| Pfaffendorf, M | 1 |
| van Zwieten, PA | 1 |
| D'Argenzio, R | 1 |
| Cavallo, P | 1 |
| Merante, D | 1 |
| Morelli, A | 1 |
| Umpierrez, GE | 1 |
| Clark, WS | 1 |
| Steen, MT | 1 |
| Levin, BE | 1 |
| Dunn-Meynell, AA | 1 |
| Goldberg, RB | 1 |
| Machado, R | 1 |
| Miossec, P | 1 |
| Lormeau, B | 1 |
| Valensi, P | 1 |
| Arthuis, F | 1 |
| Amouroux, J | 1 |
| Attali, JR | 1 |
| Timsit, J | 1 |
| Dubois-Laforgue, D | 1 |
| Blomgren, KB | 1 |
| Sundström, A | 1 |
| Steineck, G | 1 |
| Wiholm, BE | 1 |
| Beck-Nielsen, H | 2 |
| Pedersen, O | 2 |
| Lindskov, HO | 1 |
| Palmieri, G | 1 |
| Alkabes, M | 1 |
| Giulietti, M | 1 |
| Willms, B | 1 |
| Pagliano, FM | 1 |
| Bombara, R | 1 |
| Giraldi, B | 1 |
| Visca, U | 1 |
| Wildenhoff, KE | 1 |
| Sauer, H | 1 |
| Schneider, B | 1 |
| Chan, C | 1 |
| Lejeune, J | 1 |
| Trischitta, V | 1 |
| Italia, S | 1 |
| Mazzarino, S | 1 |
| Buscema, M | 1 |
| Rabuazzo, AM | 1 |
| Sangiorgio, L | 1 |
| Squatrito, S | 1 |
| Vigneri, R | 1 |
| Laurenti, O | 1 |
| Bravi, MC | 1 |
| Faldetta, MC | 1 |
| De Mattia, G | 1 |
| Riddle, M | 1 |
| Hart, J | 1 |
| Bingham, P | 1 |
| Garrison, C | 1 |
| McDaniel, P | 1 |
| Welle, S | 2 |
| Nair, KS | 2 |
| Häntzschel, U | 1 |
| Wurlitzer, M | 1 |
| Hanisch, R | 1 |
| Bothe, E | 1 |
| Dempe, A | 1 |
| Margolis, RN | 1 |
| Lockwood, D | 1 |
| Verlohren, HJ | 1 |
| Danneberg, G | 1 |
| Brunner, E | 1 |
| Pohl, A | 1 |
| Bierwolf, B | 1 |
| Draznin, B | 1 |
| Sussman, KE | 1 |
| Eckel, RH | 1 |
| Kao, M | 1 |
| Yost, T | 1 |
| Sherman, NA | 1 |
| Salo, S | 1 |
| Groop, L | 1 |
| Hother-Nielsen, O | 1 |
| Schmitz, O | 1 |
| Andersen, PH | 1 |
| Gavin, JR | 1 |
| Hughes, TA | 1 |
| Kramer, JO | 1 |
| Segrest, JP | 1 |
| Hellman, B | 10 |
| Idahl, LA | 5 |
| Lernmark, A | 3 |
| Sehlin, J | 7 |
| Täljedal, IB | 6 |
| Cabezas-Cerrato, J | 1 |
| Gómez Pérez, M | 1 |
| Marcomur, A | 1 |
| Camarero, E | 1 |
| Catalán, E | 1 |
| Fernández-Cruz, A | 1 |
| Stowers, JM | 1 |
| Martin, JM | 1 |
| Konijnendijk, W | 1 |
| Bouman, PR | 1 |
| Haupt, E | 1 |
| Beyer, J | 1 |
| Schöffling, K | 1 |
| Heine, P | 1 |
| Kewitz, H | 1 |
| Schnapperelle, U | 1 |
| Mashaly, M | 1 |
| el-Ebrashy, N | 1 |
| Higazi, AM | 1 |
| Einen, MA | 1 |
| Aziz, MT | 1 |
| Leupold, H | 1 |
| Hurme, P | 1 |
| Wahlquist, Y | 1 |
| Weber, B | 1 |
| Bloom, A | 1 |
| Danielsson, A | 1 |
| Täljedal, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Metformin Pharmacology in Human Cancers[NCT03477162] | Early Phase 1 | 18 participants (Actual) | Interventional | 2018-05-15 | Terminated (stopped due to Enrollment was closed as efforts had become more challenging, and the lab indicated that they were able to obtain their primary objective with the number that had already been enrolled.) | ||
| Effectiveness of the Treatment With Dapagliflozin and Metformin Compared to Metformin Monotherapy for Weight Loss on Diabetic and Prediabetic Patients With Obesity Class III[NCT03968224] | Phase 2/Phase 3 | 90 participants (Anticipated) | Interventional | 2018-07-07 | Recruiting | ||
| Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The Prime Study[NCT03031821] | Phase 3 | 168 participants (Actual) | Interventional | 2018-07-12 | Terminated (stopped due to Manufacturer discontinued the production of study drugs.) | ||
| Financial Incentives and SMS to Improve African American Womens' Glycemic Control: Friends & Relatives Improving the Effectiveness of Networks for Diabetes Support Through Text Messaging (FRIENDS Text)[NCT02384265] | 41 participants (Actual) | Interventional | 2012-06-21 | Completed | |||
| A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the EndoBarrier® System for Glycemic Improvement in Patients With Inadequately Controlled Type 2 Diabetes and Obesity[NCT04101669] | 240 participants (Anticipated) | Interventional | 2019-09-09 | Recruiting | |||
| Effect of Metformin Glycinate on Postprandial Lipemia, Glycemic Control and Oxidation Markers in Type 2 Diabetes Patients[NCT02064881] | Phase 2/Phase 3 | 72 participants (Anticipated) | Interventional | 2015-10-31 | Recruiting | ||
| A Pilot Study to Evaluate Eli Lilly's Insulin Dosing Algorithm to Control Glycemia in Insulin-treated Adults With Type 2 Diabetes[NCT05514080] | 10 participants (Actual) | Interventional | 2019-12-06 | Completed | |||
| A 16-wk, Uni-center, Randomized, Double-blind, Parallel, Phase 3b Trial to Evaluate Efficacy of Saxagliptin + Dapagliflozin vs.Dapagliflozin With Regard to EGP in T2DM With Insufficient Glycemic Control on Metformin+/-Sulfonylurea Therapy[NCT02613897] | 56 participants (Actual) | Interventional | 2016-01-31 | Completed | |||
| The TELE-DD Project: a Nurse-led Randomised Controlled Trial on Treatment Adherence in Patients With Type 2 Diabetes and Comorbid Depression[NCT04097483] | 428 participants (Actual) | Interventional | 2017-01-31 | Completed | |||
| Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?[NCT02879409] | 150 participants (Anticipated) | Interventional | 2016-11-30 | Active, not recruiting | |||
| The Effects of Metformin on Vascular Structure and Function in Subjects With the Metabolic Syndrome (MET Trial)[NCT00105066] | Phase 2 | 77 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| The Assessment of the Effect of Metformin and Its Serum Concentration on the Concentration of Substances Associated With the Production of Nitric Oxide in Patients With Impaired Carbohydrate Metabolism[NCT03398356] | Phase 4 | 47 participants (Actual) | Interventional | 2017-10-20 | Completed | ||
| Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes[NCT04943692] | Phase 3 | 500 participants (Anticipated) | Interventional | 2021-08-31 | Suspended (stopped due to Administrative decision of the investigation direction) | ||
| Safety and Efficacy of Metformin Glycinate vs Metformin Hydrochloride on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes Patients[NCT01386671] | Phase 3 | 203 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To determine the concentration of metformin in adipose tissue. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 70 |
To determine the concentration of metformin in plasma. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/mL (Median) |
|---|---|
| Metformin | 450 |
To determine the concentration of metformin in tumor-adjacent normal tissue. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 749 |
To determine the concentration of metformin in whole blood. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/mL (Median) |
|---|---|
| Metformin | 514 |
To determine the intra-tumor concentrations of metformin, with a standard deviation ≤25% of the mean, in patients with solid tumors of thoracic origin administered metformin extended release. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 1290 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Baseline FSG | 3rd Month FSG | |
| Metformin ( 002 Group) | 6.2 | 6.5 |
| Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | μU/ml (Mean) | |
|---|---|---|
| Baseline FSI | 3rd month FSI | |
| Metformin ( 002 Group) | 13.0 | 13.9 |
| Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |
|---|---|---|
| Baseline HbA1c | 3rd month HbA1c | |
| Metformin ( 002 Group) | 7.8 | 7.0 |
| Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |||
|---|---|---|---|---|
| Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
| Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
| Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | Score on a scale ( SI unit) (Mean) | |||
|---|---|---|---|---|
| Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
| Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
| Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mg/dl (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
| Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
| Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
Change in BMI (body mass index) from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | Kg/m^2 (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -0.8 |
| DAPA (Dapagliflozin Plus Placebo) | -0.66 |
| PCB (Placebo Plus Placebo) | 0.16 |
Change in body weight from baseline to 16 weeks (NCT02613897)
Timeframe: Baseline to 16 weeks
| Intervention | Kg (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -2.28 |
| DAPA (Dapagliflozin Plus Placebo) | -1.76 |
| PCB (Placebo Plus Placebo) | 0.26 |
A measure of the change in fasting plasma glucagon from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | mg/dl (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -28.52 |
| DAPA (Dapagliflozin Plus Placebo) | 26.89 |
| PCB (Placebo Plus Placebo) | 6.88 |
Measure of change in Free Fatty Acids from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | mEq/L (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -0.06 |
| DAPA (Dapagliflozin Plus Placebo) | -0.01 |
| PCB (Placebo Plus Placebo) | 0.00 |
Change in percentage of glucose oxidation from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | percentage of oxidation (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -22.07 |
| DAPA (Dapagliflozin Plus Placebo) | -46.54 |
| PCB (Placebo Plus Placebo) | 4.65 |
Change in lipid oxidation percentage from baseline to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | percentage of oxidation (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -11.87 |
| DAPA (Dapagliflozin Plus Placebo) | 22.02 |
| PCB (Placebo Plus Placebo) | -6.69 |
Change in blood glucose level measured over a 3 month period from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | percentage change in blood glucose level (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -1.67 |
| DAPA (Dapagliflozin Plus Placebo) | -1.46 |
| PCB (Placebo Plus Placebo) | 0.44 |
Measure of change in OGTT from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | mg/dl (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -49.62 |
| DAPA (Dapagliflozin Plus Placebo) | -44.24 |
| PCB (Placebo Plus Placebo) | 20.26 |
All subjects received a Double-Tracer Oral Glucose Tolerance Test (OGTT) with 75g of glucose containing 14C-glucose together with intravenous primed-continuous infusion of 3(3H)-glucose for 240 minutes, at baseline (prior to) and after 16 weeks of therapy. Blood and urine samples were obtained during the OGTT to determine EGP. (NCT02613897)
Timeframe: Baseline and 16 weeks
| Intervention | mg/kg*min (Mean) | |
|---|---|---|
| Baseline Measurement | 16 weeks | |
| DAPA (Dapagliflozin Plus Placebo) | 2.56 | 2.8 |
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | 2.45 | 2.4 |
| PCB (Placebo Plus Placebo) | 1.95 | 2.15 |
(NCT00105066)
Timeframe: Baseline and 4.5 months
| Intervention | meters / second (Mean) |
|---|---|
| Placebo | -7.2 |
| Metformin | -7.3 |
to evaluate improvement in endothelial function (NCT00105066)
Timeframe: Baseline and 4.5 months
| Intervention | percentage change in diameter (Mean) |
|---|---|
| Placebo | 8.8 |
| Metformin | 10.5 |
Homeostatic Model Assessment of insulin sensitivity (NCT00105066)
Timeframe: 4.5 months
| Intervention | HOMA Score (Mean) |
|---|---|
| Placebo | 57.4 |
| Metformin | 64.5 |
ADMA- asymmetric dimethylarginine-serum concentration (NCT03398356)
Timeframe: before study start; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 0.51 | 0.52 | 0.50 |
| Group B | 0.57 | 0.55 | 0.52 |
arginine serum concentration (NCT03398356)
Timeframe: Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 112.18 | 107.72 | 104.72 |
| Group B | 111.72 | 97.69 | 103.76 |
serum concentration of the citrulline (NCT03398356)
Timeframe: Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 21.73 | 25.95 | 26.93 |
| Group B | 28.08 | 27.01 | 29.77 |
DMA- dimethylamine, serum concentration (NCT03398356)
Timeframe: Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 1.71 | 1.63 | 1.62 |
| Group B | 2.07 | 1.89 | 1.84 |
the serum concentration of the studied drug-metformin (NCT03398356)
Timeframe: 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 4.36 | 5.09 | 4.66 |
| Group B | 4.25 | 7.42 | 4.01 |
SDMA-symmetric dimethylarginine-serum concentration (NCT03398356)
Timeframe: Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 0.40 | 0.41 | 0.39 |
| Group B | 0.45 | 0.42 | 0.39 |
6 reviews available for glyburide and Obesity
| Article | Year |
|---|---|
Metformin for prevention of hypertensive disorders of pregnancy in women with gestational diabetes or obesity: systematic review and meta-analysis of randomized trials.
Topics: Bayes Theorem; Diabetes, Gestational; Female; Glyburide; Humans; Hypertension, Pregnancy-Induced; In | 2018 |
[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Carbamates; Contraindications; Cyclohexanes; Diab | 2003 |
[Should the occurrence of a first coronary event change the management of diabetes?].
Topics: Acidosis, Lactic; Acute Disease; Adrenergic beta-Antagonists; Blood Glucose; Cardiovascular Agents; | 2000 |
[What is achieved by the therapy with oral antidiabetics?].
Topics: Administration, Oral; Adult; Biguanides; Chlorpropamide; Diabetes Mellitus; Diabetic Angiopathies; D | 1976 |
Oral treatment in diabetes.
Topics: Acetohexamide; Acidosis; Administration, Oral; Animals; Biguanides; Cardiovascular Diseases; Chlorpr | 1972 |
The role of calcium in insulin secretion.
Topics: Animals; Butyrates; Calcium; Calcium Isotopes; Cyclic AMP; Glucose; Glyburide; Hyperglycemia; Insuli | 1973 |
18 trials available for glyburide and Obesity
| Article | Year |
|---|---|
A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; F | 2013 |
Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy.
Topics: Adipocytes; Adiponectin; Adipose Tissue; Adult; Aged; Biopsy; Chromans; Culture Media, Conditioned; | 2003 |
Does bromocriptine improve glycemic control of obese type-2 diabetics?
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Bromocriptine; Diabetes Mellitus, Type 2; Dopamine Agon | 2004 |
Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
Topics: Adult; Aged; Appetite Depressants; Blood Glucose; Cyclobutanes; Diabetes Mellitus, Type 2; Double-Bl | 2004 |
Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy.
Topics: Adiponectin; Blood Glucose; Body Composition; C-Reactive Protein; Cross-Over Studies; Diabetes Melli | 2004 |
Efficacy of glimepiride in Japanese type 2 diabetic subjects.
Topics: Aged; Asian People; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fe | 2005 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years.
Topics: Adult; Aged; Blood Glucose; Body Weight; Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type | 1995 |
Metabolic effects of omega-3 fatty acids in type 2 (non-insulin-dependent) diabetic patients.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dietary Fats, Unsatur | 1993 |
Sulfonylurea treatment prevents recurrence of hyperglycemia in obese African-American patients with a history of hyperglycemic crises.
Topics: Adult; Black or African American; Black People; Blood Glucose; C-Peptide; Combined Modality Therapy; | 1997 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Comparison of combined therapies in treatment of secondary failure to glyburide.
Topics: Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Administra | 1992 |
[Evaluation of the efficacy of metformin-glibenclamide treatment in overweight non-insulin dependent diabetics].
Topics: Adult; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glybu | 1992 |
Combined therapy for obese type 2 diabetes: suppertime mixed insulin with daytime sulfonylurea.
Topics: Adult; Blood Glucose; C-Peptide; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Adm | 1992 |
U.K. prospective diabetes study. II. Reduction in HbA1c with basal insulin supplement, sulfonylurea, or biguanide therapy in maturity-onset diabetes. A multicenter study.
Topics: Adult; Aged; Blood Glucose; Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Gl | 1985 |
Combination of two sulfonylureas. Does it make sense.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Therapy, | 1988 |
[The influence of various sulphonylurea derivatives on the oral glucose-tolerance tests in healthy subjects and obese and maturity-onset diabetics (author's transl)].
Topics: Administration, Oral; Adult; Blood Glucose; Diabetes Mellitus; Glucose; Glucose Tolerance Test; Glyb | 1974 |
Dose-response relationships of tolbutamide and glibenclamide in diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Clinical Trials as Topic; Colorimetry; Diabetes Mellitus; Dose-Response | 1974 |
64 other studies available for glyburide and Obesity
| Article | Year |
|---|---|
E4orf1-induced reduction in endogenous insulin level is independent of pancreas endocrine function.
Topics: Adenovirus E4 Proteins; Animals; Blood Glucose; Doxycycline; Glucagon; Glucose; Glyburide; Hyperinsu | 2022 |
Glibenclamide promotes FGF21 secretion in interscapular BAT and attenuates depression-like behaviors in male mice with HFD-induced obesity.
Topics: Adipose Tissue, Brown; Animals; Depression; Diet, High-Fat; Fibroblast Growth Factors; Glyburide; Hy | 2023 |
Glibenclamide restores dopaminergic reward circuitry in obese mice through interscauplar brown adipose tissue.
Topics: Adipose Tissue, Brown; Animals; Cells, Cultured; Cytoprotection; Diet, High-Fat; Dopaminergic Neuron | 2020 |
Chronic Glibenclamide Treatment Attenuates Walker-256 Tumour Growth in Prediabetic Obese Rats.
Topics: Animals; Cachexia; Cell Line, Tumor; Cell Proliferation; Glucose; Glyburide; Hyperinsulinism; Hypogl | 2017 |
Glyburide and retinoic acid synergize to promote wound healing by anti-inflammation and RIP140 degradation.
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cells, Cultured; Diet, High-Fat; Drug S | 2018 |
Impaired vascular KATP function attenuates exercise capacity in obese zucker rats.
Topics: Acetophenones; Animals; Cromakalim; Enzyme Inhibitors; Glyburide; Humans; Hypoglycemic Agents; Male; | 2013 |
Insulin Activates Vagal Afferent Neurons Including those Innervating Pancreas via Insulin Cascade and Ca(2+) Influx: Its Dysfunction in IRS2-KO Mice with Hyperphagic Obesity.
Topics: Animals; Biological Transport; Calcium; Dose-Response Relationship, Drug; Eating; Gene Knockout Tech | 2013 |
Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance.
Topics: 3T3-L1 Cells; Adipose Tissue; Animals; Carrier Proteins; Caspase 1; Fatty Acids, Monounsaturated; Fl | 2014 |
Isoliquiritigenin is a potent inhibitor of NLRP3 inflammasome activation and diet-induced adipose tissue inflammation.
Topics: Adipose Tissue, White; Animals; Anti-Inflammatory Agents; Carrier Proteins; Cell Line, Tumor; Chalco | 2014 |
Soluble epoxide hydrolase inhibition improves coronary endothelial function and prevents the development of cardiac alterations in obese insulin-resistant mice.
Topics: Animals; Benzoates; Blood Glucose; Coronary Vessels; Disease Models, Animal; Dose-Response Relations | 2015 |
Endoplasmic reticulum stress is increased in adipose tissue of women with gestational diabetes.
Topics: Adipose Tissue; Adult; Biomarkers; Caspase 1; Connexins; Diabetes, Gestational; Endoplasmic Reticulu | 2015 |
Glibenclamide treatment blocks metabolic dysfunctions and improves vagal activity in monosodium glutamate-obese male rats.
Topics: Adipose Tissue; Animals; Autonomic Nervous System; Blood Glucose; Body Weight; Eating; Glyburide; Hy | 2017 |
Downregulation of Kir6.1/SUR2B channels in the obese rat aorta.
Topics: Animals; Aorta; ATP-Binding Cassette Transporters; Blood Pressure; Blotting, Western; Down-Regulatio | 2009 |
K(ATP)-mediated vasodilation is impaired in obese Zucker rats.
Topics: Animals; Arterioles; Cromakalim; Dose-Response Relationship, Drug; Glyburide; Hypoglycemic Agents; I | 2008 |
Adipocyte-derived factor reduces vasodilatory capability in ob-/ob- mice.
Topics: Adenosine; Adipocytes; Animals; Arterioles; Glyburide; Hypoglycemic Agents; Intra-Abdominal Fat; KAT | 2009 |
Maternal serum adiponectin multimers in gestational diabetes.
Topics: Adiponectin; Adult; Body Mass Index; Case-Control Studies; Cross-Sectional Studies; Diabetes, Gestat | 2009 |
Impaired blood pressure recovery to hemorrhage in obese Zucker rats with orthopedic trauma.
Topics: Animals; Arterioles; Blood Pressure; Disease Models, Animal; Dose-Response Relationship, Drug; Femor | 2012 |
The effect of maternal obesity on pregnancy outcomes of women with gestational diabetes controlled with diet only, glyburide, or insulin.
Topics: Comorbidity; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Logisti | 2012 |
Urinary PC-1 and N-acetyl-beta-D-glucosaminidase activity in patients with type 2 diabetes treated with metformin, gliclazide or glibenclamide.
Topics: Acetylglucosaminidase; Administration, Oral; Adult; Aged; Creatinine; Diabetes Mellitus, Type 2; Fem | 2003 |
Comparison of the effects of glimepiride and glibenclamide on adipose tissue tumour necrosis factor-alpha mRNA expression and cellularity.
Topics: Adipose Tissue; Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2004 |
The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics.
Topics: Aged; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Femal | 1993 |
Intracellular glucose metabolism after long term metabolic control with glyburide: improved glucose oxidation with unchanged glycogen synthase activity.
Topics: Blood Glucose; Body Composition; Body Mass Index; C-Peptide; Calorimetry, Indirect; Diabetes Mellitu | 1993 |
Bedtime insulin added to daytime sulfonylureas improves glycemic control in uncontrolled type II diabetes.
Topics: Adult; Aged; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glipizide; Gly | 1993 |
Rat inwardly rectifying potassium channel Kir6.2: cloning electrophysiological characterization, and decreased expression in pancreatic islets of male Zucker diabetic fatty rats.
Topics: Adenosine Triphosphate; Amino Acid Sequence; Animals; Base Sequence; Cattle; Cell Line; Cloning, Mol | 1996 |
Pharmacodynamic behaviour of isolated resistance vessels obtained from hypertensive-diabetic rats.
Topics: Animals; Benzopyrans; Blood Glucose; Calcium Channels; Calcium Chloride; Cromakalim; Glyburide; Hype | 1996 |
[Comparison of two treatment models in type-II diabetic patients with poor metabolic control: Preformed combination of glibenclamide 2,5 mg + metformin 400 mg or mono-therapy with sulfonylurea at maximal doses? An evaluation at six months].
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Combinatio | 1996 |
In vivo and in vitro regulation of [3H]glyburide binding to brain sulfonylurea receptors in obesity-prone and resistant rats by glucose.
Topics: Animals; ATP-Binding Cassette Transporters; Brain Chemistry; Carotid Arteries; Diuretics, Osmotic; E | 1997 |
Atypical ketoacidosis in type 2 diabetes.
Topics: Adult; Ambulatory Care; Clinical Protocols; Diabetes Complications; Diabetes Mellitus; Diabetes Mell | 1998 |
Bone amyloidoma in a diabetic patient with morbid obesity.
Topics: Amyloidosis; Bone Diseases; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Gl | 1999 |
Obesity and treatment of diabetes with glyburide may both be risk factors for acute pancreatitis.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Case-Control Studies; Cohort Studies; Diabetes Mellit | 2002 |
Increased insulin sensitivity and cellular insulin binding in obese diabetics following treatment with glibenclamide.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus; Female; Glucose Tolerance Test; Glyburide; Humans; In | 1979 |
[Treatment of overweight diabetics with a combination of glibenclamide and phenformin].
Topics: Adult; Diabetes Mellitus; Drug Combinations; Female; Glyburide; Humans; Male; Middle Aged; Obesity; | 1977 |
[Biguanides in the treatment of obesity].
Topics: Biguanides; Diabetes Mellitus; Drug Therapy, Combination; Glyburide; Humans; Insulin; Obesity; Phenf | 1978 |
[The importance of serum insulin determination in the diagnosis and treatment of diabetes mellitus (author's transl)].
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diet Therapy; Dose-Response Relationshi | 1975 |
[Changes in lipid metabolism in a case of associated primary hypothyroidism, obesity and diabetes mellitus].
Topics: Aged; Cholesterol; Clofibrate; Diabetes Complications; Diabetes Mellitus; Female; Glyburide; Humans; | 1976 |
Blood ketone body disappearance rate in diabetics and normals after rapid infusion of dl-3-hydroxybutyrate. Studies before and after diabetic treatment.
Topics: Acetoacetates; Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 1; | 1976 |
Reduced sensitivity to dexamethasone of pancreatic islets from obese (fa/fa) rats.
Topics: Animals; Cells, Cultured; Dexamethasone; Female; Glyburide; Insulin; Insulin Secretion; Islets of La | 1992 |
Failure of glyburide and insulin treatment to decrease leucine flux in obese type II diabetic patients.
Topics: Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Insulin; Leucine; Middle Aged; Obesity | 1990 |
[Treatment of newly diagnosed type II diabetic patients with special reference to prescribing glibenclamide in low doses].
Topics: Aged; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Diabetic; Dose-Response Rel | 1989 |
Hepatic glycogen synthase phosphatase and phosphorylase phosphatase activities are increased in obese (fa/fa) hyperinsulinemic Zucker rats: effects of glyburide administration.
Topics: Animals; Endoplasmic Reticulum; Female; Glucose-6-Phosphate; Glucosephosphates; Glyburide; Glycogen; | 1987 |
Effect of a sulfonylurea and insulin on energy expenditure in type II diabetes mellitus.
Topics: Blood Glucose; Blood Urea Nitrogen; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Energy | 1988 |
[Insulin therapy of obese diabetic patients? Consequences for the evaluation of insulin secretion and metabolic behavior].
Topics: Combined Modality Therapy; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Diabetic; Energy Meta | 1987 |
Possible role of cytosolic free calcium concentrations in mediating insulin resistance of obesity and hyperinsulinemia.
Topics: Adipose Tissue; Adult; Biopsy; Calcium; Cytosol; Deoxyglucose; Female; Glyburide; Humans; Hyperinsul | 1988 |
In vivo action of glibenclamide in obese subjects with mild type 2 (non-insulin dependent) diabetes.
Topics: Adult; Blood Glucose; C-Peptide; Circadian Rhythm; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fem | 1988 |
Dual actions of sulfonylureas and glyburide. Receptor and post-receptor effects.
Topics: Adipose Tissue; Animals; Cells, Cultured; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mel | 1985 |
Effects of glyburide therapy on lipoproteins in non-insulin-dependent diabetes mellitus.
Topics: Cholesterol; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Evaluation Studies as Topic; Glyburide; H | 1985 |
Iodoacetamide-induced sensitization of the pancreatic beta-cells to glucose stimulation.
Topics: Amides; Animals; Calcium; Carbon Isotopes; Dithiothreitol; Epinephrine; Female; Fructosephosphates; | 1973 |
[Dynamics of insulin secretion promoted by amino acids in essential obesity in women].
Topics: Administration, Oral; Adult; Amino Acids; Body Weight; Female; Glucose Tolerance Test; Glyburide; Hu | 1973 |
Insulin and growth hormone secretion in rats with ventromedial hypothalamic lesions maintained on restricted food intake.
Topics: Animals; Blood Glucose; Diet; Female; Food Deprivation; Glyburide; Growth Hormone; Hypothalamus; Ins | 1974 |
The pancreatic beta-cell recognition of insulin secretagogues. Comparisons of glucose with glyceraldehyde isomers and dihydroxyacetone.
Topics: Acetone; Animals; Arginine; Calcium; Carbon Radioisotopes; Dinitrophenols; Epinephrine; Female; Gluc | 1974 |
Uptake of glibornuride by microdissected pancreatic islets.
Topics: Animals; Biological Transport; Camphanes; Carbon Radioisotopes; Female; Glyburide; Hypoglycemic Agen | 1974 |
Factors affecting the uptake of glibenclamide in microdissected pancreatic islets rich in beta-cells.
Topics: Albumins; Animals; Carbon Radioisotopes; Cell Membrane Permeability; Female; Glyburide; Hyperglycemi | 1974 |
Oral management of uncomplicated maturity onset diabetes.
Topics: Adult; Aged; Biguanides; Chlorpropamide; Diabetes Mellitus; Diet; Drug Combinations; Glucose Toleran | 1974 |
[Studies on the course of mass screening in discovered diabetic patients].
Topics: Adolescent; Adult; Aged; Biguanides; Child; Diabetes Mellitus; Diet, Diabetic; Female; Glyburide; Hu | 1974 |
Pancreatic -cell function and content of 6-phosphogluconate.
Topics: Animals; Butyrates; Calcium; Cyclic AMP; Epinephrine; Female; Gluconates; Glucose; Glucosephosphates | 1971 |
Effects of glucose and other modifiers of insulin release on the oxidative metabolism of amino acids in micro-dissected pancreatic islets.
Topics: Alanine; Amino Acids; Animals; Arginine; Carbon Isotopes; Citrates; Cyclic AMP; Depression, Chemical | 1971 |
Pancreatic islet levels of citrate under conditions of stimulated and inhibited insulin release.
Topics: Animals; Butyrates; Calcium; Caprylates; Citrates; Cyclic AMP; Dose-Response Relationship, Drug; Epi | 1972 |
Transport and storage of 5-hydroxytryptamine in pancreatic -cells.
Topics: Animals; Biological Transport; Carbon Isotopes; Chromatography, Gel; Diazoxide; Glucose; Glyburide; | 1972 |
Transport of L-leucine and D-leucine into pancreatic -cells with reference to the mechanisms of amino acid-induced insulin release.
Topics: Amino Acids; Animals; Biological Transport; Carbon Isotopes; Cells; Extracellular Space; Glyburide; | 1972 |
Insulin release in children with diet-treated diabetes.
Topics: Adolescent; Blood Glucose; Child; Child, Preschool; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis | 1972 |
Oral therapy in diabetes.
Topics: Acetohexamide; Administration, Oral; Animals; Chlorpropamide; Diabetes Mellitus; Diet Therapy; Evalu | 1972 |
Uptake and oxidation of glutamic acid in mammalian pancreatic islets.
Topics: Alanine; Animals; Arginine; Carbon Isotopes; Female; Galactose; Glucose; Glutamates; Glyburide; Hype | 1972 |
Levels of -ketoglutarate and glutamate in stimulated pancreatic -cells.
Topics: Animals; Carbutamide; Chemical Phenomena; Chemistry; Depression, Chemical; Diazoxide; Female; Fluoro | 1970 |
Uptake of alanine, arginine and leucine by mammalian pancreatic beta-cells.
Topics: Alanine; Animals; Arginine; Carbon Isotopes; Diazoxide; Fructose; Glucose; Glyburide; Hyperglycemia; | 1971 |